Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia

References

• Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–3987.
   PubMed Web of Science ®Google Scholar
• Karrman K, Johansson B. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2017;56(2):89–116.
   PubMed Web of Science ®Google Scholar
• Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347–357.
   PubMed Web of Science ®Google Scholar
• Venkataraman V, Massoth LR, Sullivan RJ, et al. Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. Pediatr Blood Cancer. 2020;67(5):e28200.
   PubMed Web of Science ®Google Scholar
• Richard-Carpentier G, Jabbour E, Short NJ, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212–218.
   PubMed Web of Science ®Google Scholar
• Verbeke D, Gielen O, Jacobs K, et al. Ruxolitinib synergizes with dexamethasone for the treatment of t-cell acute lymphoblastic leukemia. Hemasphere. 2019;3(6):e310.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Gokbuget N, Advani A, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020;88:106283.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E. Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat it. Curr Oncol Rep. 2017;19(1):6.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Kruse A, Abdel-Azim N, Kim HN, et al. Minimal residual disease detection in acute lymphoblastic leukemia. Int J Mol Sci. 2020;21(3):1054.
   Web of Science ®Google Scholar
• Rathe M, Preiss B, Marquart HV, et al. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia. APMIS. 2020;128(5):414–419.
   PubMed Web of Science ®Google Scholar
• Oberley MJ, Raikar SS, Wertheim GB, et al. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020;34(7):1741–1750.
   PubMed Web of Science ®Google Scholar
• Gao C, Liu SG, Yue ZX, et al. Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children. Cancer Cell Int. 2019;19(1):293.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, van der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009.
   PubMed Web of Science ®Google Scholar
• Silva KAS, Spagnol F, Farias MG, et al. Influence of minimal residual disease by multiparametric flow cytometry at day 15 of induction in risk stratification of children with B-cell acute lymphoblastic leukemia treated at a referral hospital in southern Brazil. Hematol Transfus Cell Ther. 2019;S2531–1379(19):30168-3.
   Google Scholar
• Jovanovska A, Martinova K, Kocheva S, et al. Clinical significance of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Open Access Maced J Med Sci. 2019;7(17):2818–2823.
   PubMedGoogle Scholar
• Modvig S, Madsen HO, Siitonen SM, et al. Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia. 2019;33(6):1324–1336.
   PubMed Web of Science ®Google Scholar
• Cui L, Li ZG, Chai YH, on behalf of the Chinese Children Leukemia Group (CCLG), et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China. Am J Hematol. 2018;93(7):913–920.
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:7–12.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Zhao S. Nonparametric estimation of the multivariate survivor function: the multivariate Kaplan-Meier estimator. Lifetime Data Anal. 2018;24(1):3–27.
   PubMed Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163–170.
   PubMedGoogle Scholar
• Cox DR. Regression models and life tables. J R Stat Soc. 1972;34(2):187–220.
   Google Scholar
• Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–2948.
   PubMed Web of Science ®Google Scholar
• Wei W, Chen X, Zou Y, et al. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China. BMC Pediatr. 2015;15(1):80.
   PubMed Web of Science ®Google Scholar
• Wandler AM, Huang BJ, Craig JW, et al. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020;34(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371–382.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–284.
   PubMed Web of Science ®Google Scholar
• Singh N, Agrawal N, Sood R, et al. T-ALL minimal residual disease using a simplified gating strategy and its clinico-hematologic correlation: a single center experience from North India. Indian J Hematol Blood Transfus. 2019;35(4):707–710.
   PubMed Web of Science ®Google Scholar